Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026)
Kymera Therapeutics (KYMR) reported EBT Margin of 245.06% for Q1 2026, up 9203.0% year-over-year from 2.63% in Q1 2025, and up 92.82% quarter-over-quarter from 3414.15% in Q4 2025.
Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBT Margin data on file, last reported at 245.06% in Q1 2026.
- EBT Margin for Q1 2026 came in at 245.06%, up 9203.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 698.37% (down 22544.0% YoY), and the FY2025 annual result was 892.02%, down 33567.0% from the prior year.
- EBT Margin advanced to 245.06% in Q1 2026 per KYMR's latest filing, from 3414.15% in the prior quarter.
- Over five years, EBT Margin peaked at 40.44% in Q4 2023 and troughed at 3414.15% in Q4 2025.
- A 5-year average of 901.07% and a median of 470.3% in 2022 frame the typical range for EBT Margin.
- On a YoY basis, EBT Margin climbed as much as 22575 bps in 2025 and fell as far as 232118 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 239.72% in 2022, then soared by 83 bps to 40.44% in 2023, then tumbled by 2603 bps to 1092.97% in 2024, then plunged by 212 bps to 3414.15% in 2025, then jumped by 93 bps to 245.06% in 2026.
- Business Quant data shows KYMR's EBT Margin at 245.06% in Q1 2026, 3414.15% in Q4 2025, and 3350.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -245.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -245.06% |
| Dec 31, 2025 | -3,414.15% |
| Sep 30, 2025 | -3,350.90% |
| Jun 30, 2025 | -737.76% |
| Mar 31, 2025 | -337.10% |
| Dec 31, 2024 | -1,092.97% |
| Sep 30, 2024 | -1,929.54% |
| Jun 30, 2024 | -198.78% |
| Mar 31, 2024 | -562.85% |
| Dec 31, 2023 | -40.44% |
| Sep 30, 2023 | -1,217.22% |
| Jun 30, 2023 | -263.01% |
| Mar 31, 2023 | -479.41% |
| Dec 31, 2022 | -239.72% |
| Sep 30, 2022 | -470.30% |
| Jun 30, 2022 | -354.79% |
| Mar 31, 2022 | -384.27% |
| Dec 31, 2021 | -222.88% |
| Sep 30, 2021 | -141.16% |
| Jun 30, 2021 | -133.69% |